Search Medical Condition
Please enter condition
Please choose location from dropdown

Debrecen, Hungary Clinical Trials

A listing of Debrecen, Hungary clinical trials actively recruiting patients volunteers.

RESULTS

Found (159) clinical trials

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Phase

0.0 miles

Learn More »

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody ...

Phase

0.0 miles

Learn More »

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety Efficacy and Pharmacokinetics of ARGX-113 in Patients With ITP

This is a randomized, double-blind, placebo-controlled Phase II study in which approximately 36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition to Standard-of-Care (SoC) treatment. Patients aged 18 ...

Phase

0.0 miles

Learn More »

A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose ...

Phase

0.0 miles

Learn More »

Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

The study is designed to support a pacritinib dosage selection decision. Three dosages will be evaluated, with patients randomized 1:1:1 to pacritinib 100 mg QD, pacritinib 100 mg BID, or pacritinib 200 mg BID. Randomization will be stratified by baseline platelet count (50,000/L; >50,000/L and 100,000/L; and >100,000/L). Assigned treatment ...

Phase

0.0 miles

Learn More »

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

This is a Phase 2b study in patients with moderate to severe active ulcerative colitis. Patients will either receive cobitolimod dose A, B or C at two occasions or dose B or placebo at four occasions. To ensure blindness patients receiving active treatment at two occasions will receive placebo at ...

Phase

0.0 miles

Learn More »

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy and safety study to evaluate 24 weeks of oral, once-daily relugolix (40 mg) co-administered with either 12 or 24 weeks of low-dose estradiol (1.0 mg) and norethindrone acetate (0.5 mg), compared with placebo. Approximately 600 women with endometriosis-associated pain ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

Phase

0.0 miles

Learn More »

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral ...

Phase

0.0 miles

Learn More »